| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 15 Oct 2026 |
8-K: Other Events
On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plu... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients |
| 15 Jul 2026 |
8-K: Other Events
Introductory. Crescent Biopharma, Inc., a Cayman Islands exempted company (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 8,094,793 ordinary shares, par... |
| 14 Jul 2026 |
8-K: Results of Operations and Financial Condition
Crescent Biopharma, Inc. (the “Company”) is providing the following financial information. As of June 30, 2026, the Company estimates that its cash and cash equivalents were approximately $171.6 million. |
| 03 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 2, 2026, Crescent Biopharma, Inc. (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). At the close of business on April 7, 2026, the record date for the Annual Meeting (the “Record Date”), 27,5... |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition
ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination trial with CR-001 on track to initia... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs |
| 04 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 4, 2025, by and among Crescent Biopharma, Inc., a Cayman Islands exempted company (the “Company”), and each of the Persons listed on Exhibit A attached to this... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
(a.Purpose. The purpose of the Crescent Biopharma, Inc. Executive Severance Plan (the “Plan”) is to provide severance benefits to certain employees of Crescent Biopharma, Inc. and its Affiliates (as defined below) in the event of a CIC Q... |
| 18 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +9 more
(1) Includes related party amounts of $784 and $341 as of March 31, 2025 and December 31, 2024, respectively. |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure +1 more
—GlycoMimetics Board of Directors approves 1-for-100 reverse stock split— |
| 30 May 2025 |
8-K: Other Events
As previously disclosed, GlycoMimetics, Inc., a Delaware corporation (“GlycoMimetics”), entered into an Agreement and Plan of Merger and Reorganization, dated October 28, 2024, which agreement was amended on February 14, 2025 and April 2... |
| 29 Apr 2025 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Amendment”) is made as of April 28, 2025, with respect to that certain Agreement and Plan of Merger and Reorganization (as amended to date, the “Merger Agreem... |
| 25 Feb 2025 |
8-K: Termination of a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
On February 19, 2025, GlycoMimetics, Inc. (the “Company”) received a notice from Apollomics (Hong Kong) Limited (“Apollomics”), terminating the Collaboration and License Agreement between the Company and Apollomics that was effective as ... |
| 14 Feb 2025 |
8-K: Entry into a Material Definitive Agreement
This Amended and Restated SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 14, 2025, by and among Crescent Biopharma, Inc., a Delaware corporation (“Crescent”), GlycoMimetics, Inc., a Delaware corporation (“Parent... |
| 31 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 29, 2025, each of Mr. Harout Semerjian, the Chief Executive Officer of GlycoMimetics, Inc. (the “Company”) and Mr. Brian Hahn, the Company’s Chief Financial Officer, notified the Company’s board of directors of his intent to c... |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
2 Disclaimer This presentation is for informational purposes only and only a summary of certain information related to the Company . It does not purport to be complete and does not contain all information that an investor may need to con... |
| 26 Dec 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On December 19, 2024, GlycoMimetics, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Company a... |
Loading...